In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CTS On The Rebound?

Executive Summary

In the battle for the minimally-invasive cardiac surgery market, CTS has long been seen as second fiddle to HeartPort. But while HeartPort has struggled, CTS has been growing nicely. With nearly 50% of the minimally-invasive cardiac surgery market, CTS is now the market leader and watching competitors fall by the wayside. Now the trick is convincing investors.

Related Content

Cardica: Rebuilding the Cardiac Surgery Market


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts